This information was provided by cmwmedia
Send your Press Release here.
The CTE Center at Boston University’s School of Medicine is closing in on a workable diagnosis for the neurodegenerative brain disease CTE, after studying the brains of nearly 500 deceased players who have donated their brains to science.
CTE, or Chronic Traumatic Encephalopathy, is a degenerative neurological disease caused by repeated head trauma and only diagnosable with certainty in post-mortem examinations and can lead to symptoms like violent mood swings, depression and other cognitive difficulties.
Ann McKee, chief of neuropathology at the VA Boston Healthcare System, says “If we can diagnose it, we can monitor it and test therapies to see if they’re effective in treating this disease… It would really dramatically increase our ability to point out genetic susceptibilities for this.”
While McKee is working with her team for a feasible way to diagnose and predict genetic markers for CTE, researchers at Kannalife Sciences are working to create a workable treatment for the disease.
Kannalife Sciences (“Kannalife”) is the phyto-medical company that specializes in the research & development of pharmacological products derived from botanical sources. Kannalife’s exclusive license to the patent “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”) allows the company to dogroundbreaking research and develop cannabinoid-based treatments for CTE, which is a degenerative brain disease often found in contact sports athletes.KannaLife hopes their company’s research will pave the way for the development of cannabidiol-based (CBD) drugs to help protect the brain.
Would you like to speak with Kannalife’s Douglas Brenneman to discuss the most recent developments in CTE research?
Douglas Brenneman, PhD – Scientific Advisory Board Dr. Brenneman has over 30 years of research experience as a Section Chief within the intramural program at NICHD and as a Senior Research Fellow at Johnson & Johnson. He has more than 170 scientific publications and 15 patents focused on both evaluating neurotoxic and neuroprotective substances with various Central Nervous System preparations.
To secure an interview with Dr. Breneman regarding CTE, please contact: